Circulating Folate, Vitamin B12, Homocysteine, Vitamin B12 Transport Proteins, and Risk of Prostate Cancer: a Case-Control Study, Systematic Review, and Meta-analysis

Simon M. Collin(University Hospital of North Norway), Chris Metcalfe(University Hospital of North Norway), Helga Refsum(University Hospital of North Norway), Sarah J. Lewis(University Hospital of North Norway), Luisa Zuccolo(University Hospital of North Norway), George Davey Smith(University Hospital of North Norway), Lina Chen(University Hospital of North Norway), R. Cole Harris(University Hospital of North Norway), Michael Davis(University Hospital of North Norway), Gemma Marsden(University Hospital of North Norway), Carole Johnston(University Hospital of North Norway), J. Athene Lane(University Hospital of North Norway), Marta Ebbing(University Hospital of North Norway), Kaare Harald Bønaa(University Hospital of North Norway), Ottar Nygård(University Hospital of North Norway), Per Magne Ueland(University Hospital of North Norway), Maria V. Grau(University Hospital of North Norway), John A. Baron(University Hospital of North Norway), Jenny Donovan(University Hospital of North Norway), David E. Neal(University Hospital of North Norway), Freddie C. Hamdy(University Hospital of North Norway), A. David Smith(University Hospital of North Norway), Richard M. Martin(University Hospital of North Norway)
Cancer Epidemiology Biomarkers & Prevention
June 1, 2010
Cited by 158Open Access
Full Text

Abstract

BACKGROUND: Disturbed folate metabolism is associated with an increased risk of some cancers. Our objective was to determine whether blood levels of folate, vitamin B(12), and related metabolites were associated with prostate cancer risk. METHODS: Matched case-control study nested within the U.K. population-based Prostate testing for cancer and Treatment (ProtecT) study of prostate-specific antigen-detected prostate cancer in men ages 50 to 69 years. Plasma concentrations of folate, B(12) (cobalamin), holo-haptocorrin, holo-transcobalamin total transcobalamin, and total homocysteine (tHcy) were measured in 1,461 cases and 1,507 controls. ProtecT study estimates for associations of folate, B(12), and tHcy with prostate cancer risk were included in a meta-analysis, based on a systematic review. RESULTS: In the ProtecT study, increased B(12) and holo-haptocorrin concentrations showed positive associations with prostate cancer risk [highest versus lowest quartile of B(12) odds ratio (OR) = 1.17 (95% confidence interval, 0.95-1.43); P(trend) = 0.06; highest versus lowest quartile of holo-haptocorrin OR = 1.27 (1.04-1.56); P(trend) = 0.01]; folate, holo-transcobalamin, and tHcy were not associated with prostate cancer risk. In the meta-analysis, circulating B(12) levels were associated with an increased prostate cancer risk [pooled OR = 1.10 (1.01-1.19) per 100 pmol/L increase in B(12); P = 0.002]; the pooled OR for the association of folate with prostate cancer was positive [OR = 1.11 (0.96-1.28) per 10 nmol/L; P = 0.2) and conventionally statistically significant if ProtecT (the only case-control study) was excluded [OR = 1.18 (1.00-1.40) per 10 nmol/L; P = 0.02]. CONCLUSION: Vitamin B(12) and (in cohort studies) folate were associated with increased prostate cancer risk. IMPACT: Given current controversies over mandatory fortification, further research is needed to determine whether these are causal associations.


Related Papers

No related papers found

Powered by citation graph analysis